21/02/2023 - Research

Innovative technique to improve characterisation of ventricular tachycardia substrate

A study published in JACC: Clinical electrophysiology evaluates local impedance-based mapping as a tool to identify critical components of ventricular tachycardia after myocardial infarction. It highlights its potential to improve the characterisation of ventricular tachycardia tissues and circuits. The scientists conclude that the technique is feasible and could improve the results of cardiac ablation. The work, which was performed in an animal model, involved researchers from the Heart Failure and Heart Regeneration Research Group (ICREC) at the Germans Trias i Pujol Research Institute (IGTP), the Heart Institute of the Germans Trias Hospital (iCor), the Autonomous University of Barcelona (UAB) and Boston Scientific.

16/02/2023 - Research

Nine IGTP researchers participated in the 5th Edition of #100tífiques

The #100tífiques 2023 event was held with the participation of 573 women researchers. They gave simultaneous talks during the morning to around 40,000 students aged 11 to 13 across 505 Catalan schools. The purpose of the event is to encourage children to pursue scientific and technical careers while fostering a community of shared interests between academics and industry professionals. Nine scientists working at the Germans Trias i Pujol Institute (IGTP) took part in the event.

15/02/2023 - Projects, Research

Funding of €1.2M from the Spanish Association Against Cancer for a research project on childhood liver cancer coordinated by IGTP

Encouraging news in the framework of the International Day Against Childhood Cancer. The Spanish Association Against Cancer, through its Aid Programmes, has granted 1.2 million euros to the coordinated project "Personalised Medicine for Childhood Liver Cancer". The five-year project will be coordinated by the Germans Trias i Pujol Research Institute (IGTP), under the leadership of Dr Carolina Armengol, with the participation of another four Spanish research groups. All participating groups are members of the CIBER of Hepatic and Digestive Diseases (CIBEREHD).

14/02/2023 - Innovation, Projects, Research

State funding of €1.8M to develop an advanced gene therapy for Friedreich's ataxia

The Centre for the Development of Industrial Technology (CDTI) and the Carlos III Health Institute (ISCII) will fund the project with 1.8 million euros within the R&D&I call linked to Personalised Medicine and Advanced Therapies in the framework of the Strategic Project for the Recovery and Economic Transformation for Vanguard Health (PERTE for Vanguard Health) in gene therapy for Friedreich's ataxia.

09/02/2023 - Campus Can Ruti, Conferences

The Can Ruti Working Group Women in Science (WiS) looks back on 5 years of activity and forward to the future of gender perspective and intersectionality in science

To celebrate the Day of Women and Girls in Science on 11 February the Can Ruti Working Group Women in Science (WiS) today held its 5^th symposium focussed on Integrating Intersectionality and Gender Perspective in Research, hosted by the IGTP.

06/02/2023 - Projects, Research

GCAT-IGTP and ISGlobal launch third year of COVICAT-CONTENT study

The COVICAT-CONTENT 2023 study begins today, with the aim of monitoring COVID-19 in different cohorts in Catalonia and the rest of Spain. Researchers from the Barcelona Institute for Global Health (ISGlobal) and the GCAT'Genomes for Life project of the Germans Trias i Pujol Research Institute (IGTP) evaluate the genetic and epidemiological determinants associated with the disease, as well as the long-term effects of the pandemic on people's physical and mental health and the evolution of the immune response. In this way, the objective is to help define predictive models and control policies for similar situations in the future.

02/02/2023 - Projects, Research

IGTP will coordinate a European project to improve the diagnosis and treatment of neurofibromatoses

Researchers from the Clinical Genomics Group at Germans Trias i Pujol Research Institute (IGTP) and the Genetics Service at Germans Trias i Pujol Hospital (HUGTiP) will coordinate the project EURONET-NF, which aims to improve genetic diagnosis for patients with neurofibromatoses and schwannomatosis (NF-SWN). The project, which involves 6 countries, has been awarded around €1.6 million in funding by the European Union for the next 3 years.Researchers from the Clinical Genomics Group at Germans Trias i Pujol Research Institute (IGTP) and the Genetics Service at Germans Trias i Pujol Hospital (HUGTiP) will coordinate the project EURONET-NF, which aims to improve genetic diagnosis for patients with neurofibromatoses and schwannomatosis (NF-SWN). The project, which involves 6 countries, has been awarded around €1.6 million in funding by the European Union for the next 3 years.

23/01/2023 - Research

A new study with the GCAT cohort analyses pigmentary traits and their relationship with diseases

Researchers from the GCAT|Genomes for Life project of the IGTP have analysed the genetic basis of 13 pigment traits and their association with diseases. The work has been published this month in Genes. 

20/01/2023 - Research

The Legionellosis Study Group consolidates its position as a reference research group in Catalonia

The Public Health Agency of Catalonia (ASPCAT) has increased the budget granted to the Legionellosis Study Group (GELeg) of the Clinical and Environmental Infectious Diseases Research Group (CEID) of the Germans Trias i Pujol Research Institute (IGTP), ratifying its confidence in the resolution of Legionella outbreaks. The increase is almost double the budget items of previous years and will expand the scope of the work carried out in the laboratory.

18/01/2023 - Innovation

Nimble Diagnostics closes a financing round of one million euros

NIMBLE Diagnostics, a spin-off from the Germans Trias i Pujol Research Institute (IGTP), the Polytechnic University of Catalonia – BarcelonaTech (UPC) and the University of Barcelona (UB), has successfully closed a funding round led by Grow Ventures together with Namarel Ventures and Inveniam Group where they have secured more than one million euros. NIMBLE is developing the first medical device to monitor patients with implanted stents, thus avoiding serious complications and improving the clinical management of millions of patients each year.